Journal of Cystic Fibrosis
Volume 11, Issue 1 , Pages 2-7 , January 2012

Prevalence and impact on FEV1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with Cystic Fibrosis: A single-center, case control study of 165 patients

  • E. Vanderhelst

      Affiliations

    • Universitair Ziekenhuis Brussel UZB, CF Center, Brussels, Belgium
    • Universitair Ziekenhuis Brussel UZB, Respiratory Division, Brussels, Belgium
    • Corresponding Author InformationCorresponding author at: Universitair Ziekenhuis Brussel, Laarbeeklaan 101, B-1090 Brussels, Belgium. Tel.: +32 4774675; fax: +32 4776352.
    • ,
  • L. De Meirleir

      Affiliations

    • Universitair Ziekenhuis Brussel UZB, CF Center, Brussels, Belgium
    • Universitair Ziekenhuis Brussel UZB, Respiratory Division, Brussels, Belgium
    • ,
  • S. Verbanck

      Affiliations

    • Universitair Ziekenhuis Brussel UZB, Respiratory Division, Brussels, Belgium
    • ,
  • D. Piérard

      Affiliations

    • Universitair Ziekenhuis Brussel UZB, Microbiology, Brussels, Belgium
    • ,
  • W. Vincken

      Affiliations

    • Universitair Ziekenhuis Brussel UZB, Respiratory Division, Brussels, Belgium
    • ,
  • A. Malfroot

      Affiliations

    • Universitair Ziekenhuis Brussel UZB, CF Center, Brussels, Belgium

Received 3 May 2011 ,Revised 11 August 2011 ,Accepted 14 August 2011.

References 

  1. Rosenstein BJ, Zeitlin PL. Cystic fibrosis. Lancet. 1998;351:277–282
  2. Boxerbaum B, Jacobs MR, Cechner RL. Prevalence and significance of methicilin-resistant Staphylococcus aureus in patients with cystic fibrosis. Pediatr Pulm. 1988;4:159–163
  3. Miall LS, McGinley NT, Brownlee KG, Conway SP. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child. 2001;84:160–162
  4. Goodrich J, Sutton-Shields TN, Kerr A, Wedd JP, Miller MB, Gilligan PH. Prevalence of community-associated methicillin-resistant Staphyloccus aureus in patients with cystic fibrosis. J Clin Microbiol. 2009;47:1231–1233
  5. Giron RM, Buendia B, Pinedo C, Casanova A, Hoyos N, Ancochea J. Methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. Enferm Infecc Microbiol Clin. 2009;27:85–88
  6. Ren C, Morgan WJ, Konstan MW, Schechter MS, Wagener JS, Fisher KA, et al. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulm. 2007;42:513–518
  7. Annual report from the Cystic Fibrosis Foundation 2008.
  8. Spicuzza L, Sciuto C, Vitaliti G, Di Dio G, Leonardi S, La Rosa M. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis. 2009;28(2):191–195
  9. Steinkamp G, Wiedemann B, Rietschel E, Krahl A, Gielen J, Bärmeier H, et al. Prospective evaluation of emerging bacteria in cystic fibrosis. J Cyst Fibrosis. 2005;4(1):41–48
  10. Vergison A, Denis O, Deplano A, Casimir G, Claeys G, DeBaets F, et al. National survey of molecular epidemiology of Staphylococcus aureus colonization in Belgian cystic fibrosis patients. J Antimicrob Chemother. 2007;59(5):893–899
  11. Dasenbrook E, Checkley W, Merlo C, Konstan M, Lechtzin N, Boyle M. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. J Am Med Assoc. 2010;303:2386–2392
  12. Dasenbrook E, Merlo C, Diener-West M, Lechtzin N, Boyle M. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:814–821
  13. Boyle MP, Ross T, Goldberg JD. Molecular epidemiology of MRSA infection in cystic fibrosis and its clinical implications. Pediatr Pulm. 2005;28:288–289
  14. Thomas SR, Gyi KM, Gaya H, Hudson ME. Methicillin-resistant Staphylococcus aureus — impact at a national cystic fibrosis centre. J Hosp Infect. 1998;40:203–209
  15. Nadeslingam K, Conway S, Denton M. Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. J Cyst Fibros. 2005;4:49–52
  16. Stefani S, Varldo PE. Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect. 2003;9:1179–1186
  17. Glikman D, Siegel J, David M, Okoro N, Boyle-Vara S, Doweel M, et al. Complex molecular epidemiology of methicillin-resistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S. aureus. Chest. 2008;133:1381–1387
  18. Elizur A, Orscheln R, Ferkol T, Atkinson J, Dunne W, Buller R, et al. Panton-Valentine Leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest. 2007;131:1718–1725
  19. Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, et al. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation (ΔF508). N Engl J Med. 1990;323:1517–1522
  20. Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest. 1998;113:1230–1234
  21. Doe SJ, McSorley A, Isalka B, Kearns AM, Bright-Thomas R, Brennan AL, et al. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros. 2010;9:104–109

PII: S1569-1993(11)00139-1

doi: 10.1016/j.jcf.2011.08.006

Journal of Cystic Fibrosis
Volume 11, Issue 1 , Pages 2-7 , January 2012

Article Tools

* Image Usage & Resolution